| Ytd | -45.61% | |
| 1y | 56.55% |
| Open | 0.75 | Prev Close | 0.75 | Low | 0.73 | High | 0.77 | Mkt Cap | 103.17M |
| Vol | 88.48K | Avg Vol | 724.14K | EPS | -0.16 | P/E | N/A | Forward P/E | -1.41 |
| Beta | 0.69 | Short Ratio | 0.36 | Inst. Own | 19.59% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 11-05 | 50-d Avg | 0.82 | 200-d Avg | 0.99 | 1yr Est | 11.50 |
RANI News
Rani Therapeutics Holdings, Inc. (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on
HC Wainwright & Co. analyst Brandon Folkes reiterates Rani Therapeutics Hldgs (NASDAQ:RANI) w
Top analysts changed outlook on top names. See analyst ratings page for all changes.
Chardan Capital analyst Andreas Argyrides initiates coverage on Rani Therapeutics Hldgs (NASDAQ:R
Rani Therapeutics Hldgs (NASDAQ:RANI) reported quarterly losses of $(0.04) per share which beat the
Gainers Advanced Biomed (NASDAQ:ADVB) shares moved upwards by 108.6% to $14.77 during Wednesday'
RT-114 achieved systemic exposure greater than 150% relative to a matched 12mg subcutaneous dose of
Rani Therapeutics Holdings, Inc. ("Rani Therapeutics" or "Rani") (Nasdaq: RANI), a c
Rani Therapeutics Holdings, Inc. ("Rani Therapeutics" or "Rani") (NASDAQ:RANI), a cl
Rani Therapeutics Hldgs (NASDAQ:RANI) reported quarterly losses of $(0.04) per share which met the a
Canaccord Genuity analyst Edward Nash maintains Rani Therapeutics Hldgs (NASDAQ:RANI) with a Buy
HC Wainwright & Co. analyst Brandon Folkes reiterates Rani Therapeutics Hldgs (NASDAQ:RANI) w
Rani Therapeutics Hldgs (NASDAQ:RANI) reported quarterly losses of $(0.07) per share which missed th
HC Wainwright & Co. analyst Brandon Folkes reiterates Rani Therapeutics Hldgs (NASDAQ:RANI) w
PG-102 is a fc-fusion protein conjugated GLP-1/GLP-2 dual agonist in development by ProGen Co., Ltd.
Cash, cash equivalents and marketable securities as of September 30, 2025 totaled $4.1 million, comp
Biotech stocks have trailed the broader market this year, but more names are starting to show streng
HC Wainwright & Co. analyst Brandon Folkes assumes Rani Therapeutics Hldgs (NASDAQ:RANI) with
Maxim Group analyst Michael Okunewitch maintains Rani Therapeutics Hldgs (NASDAQ:RANI) with a Buy
Rani Therapeutics (NASDAQ: RANI) stock surged on licensing collaboration with Chugai and $60.3M priv
Gainers Galecto (NASDAQ: GLTO) stock rose 21.6% to $5.41 during Thursday's after-market session
Rani Therapeutics Hldgs (NASDAQ:RANI) reported quarterly losses of $(0.18) per share which beat the
Rani Therapeutics Holdings, Inc. ("Rani Therapeutics" or "Rani") (NASDAQ:RANI), a cl
https://scr.zacks.com/files/News/2025/Zacks_SCR_Research_05192025_RANI_Vandermosten.pdf